# NonSegmental Vitiligo FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/nonsegmental-vitiligo

> 6 upcoming FDA catalysts in NonSegmental Vitiligo: zasocitinib (TAK) on Mar to Jun 2027 (topline data readout); zasocitinib (TAK) on March 2027 (primary completion); ruxolitinib cream (INCY) on Apr to Jul 2027 (topline data readout); ruxolitinib cream (INCY) on April 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 24, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | NonSegmental Vitiligo | completed | "NCT06113445 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06113445)) |
| March 17, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | NonSegmental Vitiligo | completed | "NCT06113471 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06113471)) |
| Mar to Jun 2027 | [Zasocitinib topline data readout](https://sec-api.dev/pdufa/zasocitinib) | TAK | Nonsegmental Vitiligo | scheduled | "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108283)) |
| March 2027 | [Zasocitinib primary completion](https://sec-api.dev/pdufa/zasocitinib) | TAK | Nonsegmental Vitiligo | scheduled | "NCT07108283 (A Study of Zasocitinib in Adults With Nonsegmental Vitiligo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07108283)) |
| Apr to Jul 2027 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06804811 (A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804811)) |
| April 2027 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06804811 (A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06804811)) |
| Jun to Sep 2028 | [Ruxolitinib cream topline data readout](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06548360 (A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548360)) |
| June 2028 | [Ruxolitinib cream primary completion](https://sec-api.dev/pdufa/ruxolitinib-cream) | INCY | NonSegmental Vitiligo | scheduled | "NCT06548360 (A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-05 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06548360)) |

## Drugs

- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/nonsegmental-vitiligo.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NonSegmental Vitiligo FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/nonsegmental-vitiligo

```bibtex
@misc{secapidev_indications_nonsegmental_vitiligo_20261116,
  title        = {NonSegmental Vitiligo FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/nonsegmental-vitiligo}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_nonsegmental_vitiligo_20261116","title":"NonSegmental Vitiligo FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/nonsegmental-vitiligo","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
